109
Views
1
CrossRef citations to date
0
Altmetric
Reviews

An overview of the clinical use of ondansetron in preschool age children

Pages 333-339 | Published online: 28 Dec 2022

Abstract

The introduction of 5-HT3 receptor antagonist has revolutionized the prevention and treatment of nausea and vomiting in preschool aged children. These distressing symptoms, arising from multiple etiologies such as anesthesia, chemotherapy, and viral infection, are a major concern of patients and their families. Clinical research has demonstrated the antiemetic effectiveness of ondansetron in children. Although most of these studies focus primarily on preventing vomiting across the pediatric age group, they provide strong evidence for the use of ondansetron in preschool age children. For children at high risk, pediatric practice guidelines recommend ondansetron in conjunction with other antiemetics to achieve complete control of symptoms.

Introduction

Nausea and vomiting are frequently experienced in infancy and preschool age childhood (CitationIacono et al 2005). These distressing symptoms are associated with common childhood occurrences such as car travel and gastroenteritis as well as postoperative recovery and cancer-related interventions. Once considered an inconvenient but unavoidable outcome of anesthesia, surgery, chemotherapy and radiation, nausea and vomiting are now recognized as the number one concern of patients and their families (CitationEberhart et al 2002; CitationWisselo et al 2004; CitationLee 2005). Recent investigations have revealed that distress, discomfort, and disruption associated with nausea and vomiting are significant even in the youngest of patients (CitationKhalil et al 2005; CitationHoldsworth 2006). Increased awareness, availability of 5-hydroxytryptamine (5-HT3) receptor antagonists, and combined anti-emetic strategies should decrease the incidence of nausea and vomiting in this overlooked age group.

The 5-HT3 receptor antagonist ondansetron, first heralded by Lancet in 1987, was rapidly recognized as having broad applicability with significant benefits (CitationAnonymous 1987). Initially studied in patients receiving cis-platinum, ondansetron was soon shown to be effective in preventing radiation- and chemotherapy-induced nausea and vomiting (CitationGreen et al 1989). By the early 1990s, it was documented that ondansetron decreased postoperative nausea and vomiting (PONV) in adults and children (CitationLeeser and Lip 1991; CitationLitman et al 1994). In placebo-controlled and comparative studies of patients undergoing various oncologic therapies and surgical procedures, ondansetron had consistently performed in the prevention and treatment of vomiting. Unlike traditional antiemetics, ondansetron was not associated with pronounced adverse reactions such as electrocardiograph abnormalities, somnolence, dysphoria, dystonia, and confusion. Due to its favorable therapeutic index, ondansetron has become the most frequently prescribed antiemetic. For young children and other patients who cannot swallow pills, ondansetron is also available in dissolving tablets and oral liquid formulations (CitationDupuis and Nathan 2003).

Etiology

Nausea and vomiting arises from multiple etiologies. Each involves a complex series of humoral and neurological interactions resulting in the stimulation of the vomiting center, a nucleus of cells in the medulla (CitationAndrews and Hawthorn 1988). Neurotransmitters involved in this process include dopamine, acetylcholine, histamine, endorphins, serotonin, and neurokinin (NK1) (CitationPisters and Kris 1998). Receptors for these neurotransmitters are common in the vomiting center, chemoreceptor trigger zones (CTZ), and gastrointestinal (GI) tract. The vomiting center receives input from at least four sources: the CTZ, GI tract, vestibular apparatus, and cerebral cortex. The CTZ, which lie in the brain stem beneath the fourth ventricle, sense chemical abnormalities in the body and indirectly receive input from the vagus nerves. Distention and inflammation of the GI tract and other internal organs cause the release of emetogenic substances and stimulates the CTZ via the vagus. Vestibular apparatus plays a role in motion sickness while the cerebral cortex is instrumental in olfactory, emotional, and anticipatory nausea and vomiting. It is postulated that ondansetron and other 5-HT3 receptor antagonists exerts its antiemetic action both peripherally (vagus and sympathetic nerves) and centrally (CTZ and vomiting center) by blocking stimulation of serotonin receptors (CitationPisters and Kris 1998).

Postoperative nausea and vomiting

PONV, which is defined as early (0–6 hours) and delayed (6–48 hours) has been extensively studied in children due to its frequency, predictability, and economic impact. It is postulated that the surgical and anesthesia-related etiology of PONV is multifactorial, arising from direct stimulation of the CTZ by anesthetic agents (ie, nitrous oxide, opioids, anticholinesterases, and volatile gases) indirect stimulation from vagal transmission secondary to surgical manipulation (CitationWatcha and White 1992). Over 25 randomized control trials of ondansetron prophylaxis have been performed in infants and preschool aged children. In pediatric patients, PONV is the leading cause of delayed discharge and emergency readmission (CitationPatel and Hannallah 1988; CitationGold et al 1989). These patients are 50%–75% more likely to develop PONV than their adult counter parts with an incidence of 34%–50% in school age children and 20% in preschool children (CitationCohen et al 1990). The highest incidence of PONV is associated with eye muscle surgery, tonsillectomy, adenoidectomy, orchidopexy, and hernia repair reported high as 88%, 70%, 50%, and 40%, respectively (CitationLerman 1992; CitationWatcha and White 1992). Recent studies have demonstrated that the occurrence of PONV in 1- and 2-year-olds is higher than previously documented (CitationKhalil et al 2005). Risk factors for PONV in children are summarized in . Over the last three decades numerous antiemetic medications have been studied, including droperidol, metoclopramide, dimenhydrinate, promethazine, prochlorperazine, scopolamine, and corticosteroids but the greatest success has been documented with 5-HT3 receptor antagonists, in general, and ondansetron, in particular.

Table 1 Risk factors for postoperative nausea and vomiting in children

Most pediatric PONV clinical trials have focused on early PONV, grouped preschool age children with school aged children, and reported emesis, not nausea, as their determinant factor. These data do not allow for easy analysis of antiemetic response to ondansetron in younger children and antinausea response in children overall. Other study limitations include a focus on prevention as opposed to treatment, high risk procedures such as strabismus repair and adenotonsillectomy, and combined therapy evaluations. For ease of comparison, results of these studies are discussed in this chapter as the number needed to treat (NNT) within a confidence intervals of 95% (CI 95%). NNT is the number of subjects required to be treated to result in one less patient having symptoms compared with those patients who received placebo. The smaller the NTT, the more effective is the medication. If not otherwise noted, NNT is reported for placebo-controlled studies.

Meta-analyses of studies examining PONV prophylaxis with ondansetron, 50–100 µg/kg intravenously, found the NNT to be 3 (CI 95% 2–5) for early PONV (CitationTramer et al 1997). In comparison, meta-analyses of early PONV prophylactic dexamethasone (following tonsillectomy), droperidol, and metoclopramide found the NNT to be approximately 4 (CI 95% 2–6), 5 (CI 95% 3–7), and 8 (CI 95% 5–28), respectively (Steward et al 2002; CitationHenzi et al 1999, Citation2000). In children, other available 5-HT3 receptor antagonists have similar treatment profiles compared with ondansetron (CitationGan 2005).

Adverse drug reactions with ondansetron use are reported as being equal to or less than that reported in control (placebo) groups (CitationCuly et al 2001). Less than 1% of children complain of headache or dizziness. Other reported adverse responses, which are rare but serious, include electrocardiography alteration involving sodium channels changes, central nervous changes such as dyskinesias, and elevated liver enzymes (CitationGoodin and Cunningham 2002; Kovac 2002). In contrast, side-effects reported with metoclopramide such as headaches, high levels of sedation, and extrapyramidal symptoms occurred with statistically significant greater frequency (CitationDomino et al 1999). Droperidol profile is less favorable secondary to more pronounced side-effects such as somnolence and a theoretical increased risk of cardiac arrhythmia in children.

Chemotherapy-induced nausea and vomiting

In patients of all ages, chemotherapy-induced nausea and vomiting (CINV) and radiation-induced nausea and vomiting (RINV) are sited as the most common fear and the leading cause of poor compliance (CitationCoates et al 1983). The percentage of patients experiencing vomiting with specific chemotherapy agents ranges from greater than 90% with cisplatin (>50 mg/m2) to less than 10% with vincristine (CitationSchnell 2003). High, moderate, and low risk emetogenic agents are presented in .

Table 2 Emetogenic potential of chemotherapy agents risk and (%)

CINV is classified as acute, delayed, and anticipatory with severity directly related to emetogenic potential of antioncologic therapy and efficacy of prevention and treatment (Antonarakis and Hain 2005). Acute CINV, by definition, occurs within 24 hours after a chemotherapy dose. With modern antiemetic prophylaxis 76%–86% of children receiving a variety of emetogenic chemotherapy agents are emesis free (CitationFoot and Hayes 1994; CitationKusnierczyk et al 2002). Delayed CINV occurs 24 hours or more after a chemotherapy dose and may persist for 5–7 days. The incidence, patterns, and risk factors in children are poorly understood but delayed CINV is more commonly associated with the use of cisplatin, carboplatin, and/or cyclophosphamide as well as vomiting during the acute phase (CitationDupuis and Nathan 2003). Anticipatory CINV occurs prior to the administration of chemotherapy and, like delayed CINV, appears linked to poor emetic control during previous chemotherapy treatments. In children, preschool and school age, the incidence of anticipatory CINV has been reported to range from 15% to 54%, depending on research methods and antiemetic prophylaxis history (CitationFoot and Hayes 1994; CitationTyc et al 1997) These data reinforce the importance of achieving excellent emetic control in children receiving chemotherapy.

The advent of 5-HT3 receptor antagonists has markedly improved patient lives. The different available agents have shown uniform advantages over older antiemetics. Of these medications, ondansetron has been extensively studied for prophylaxis against and treatment of CINV. Most papers that examine prophylactic ondansetron use in children examine early CINV in clinical reports. There are fewer than 10 randomized, controlled studies available in this age group and only 1 with a placebo-treated control group. The remainder of the studies reviewed compare ondansetron with phenothiazine derivatives. Because chemotherapy protocols (medications, dosing, and cycles) and antiemetic regimens (dosing, route, and frequency) vary with different cancers and treatment centers, comparison among studies is problematic. In addition, placebo-controlled trials performed solely in infants and preschool aged children are unavailable.

Keeping these limitations in mind, some data can be generalized for the use of 5-HT3 receptor antagonists in preventing and treating CINV. Children 18 months to 15 years of age receiving highly emetogenic agents have been described in a systematic review as having anywhere from 25% to 100% complete or major control of acute vomiting with ondansetron therapy (CitationAntonarakis et al 2004). CitationHoldsworth et al (1995) compared ondansetron treated and non-treated pediatric patients receiving carmustine, etoposide/cytarabine or cyclophosphamide and determined the NNT as 3 (CI 95% 2–7). In a similar age group receiving high dose (4.5 mg/kg) ondansetron, CitationParker and colleagues (2001) found the NNT to prevent CINV from intrathecal methotrexate to be 2.

In comparative trials with traditional antiemetics, ondansetron has been shown to have greater efficacy. In one study, children 18 months to 15 years of age receiving an intensification chemotherapy regimen for acute lymphocytic leukemia were randomized to receive either ondansetron (3–5 mg/m2) or metoclopramide plus dexamethasone and procyclidine. Complete or major control of vomiting was achieved in 93% and 33% of children in each group, respectively (CitationDick et al 1995). In a similar study of children receiving emetogenic chemotherapy, CitationKoseoglu and colleagues (1998) also demonstrated that ondansetron produced superior relief of symptoms. In randomized, controlled studies of 5-HT3 receptor antagonists, ondansetron appeared to be equivalent to granisetron but more effective than tropisetron (CitationStiakaki et al 1999; CitationJaing et al 2004). Granisetron has a longer duration of action, which offers advantages in terms of dosing schedules.

Studies of radiation-induced nausea vomiting in young children are limited. However, in combined studies with older children superior control of emesis, compared with phenothiazine derivatives, was demonstrated with ondansetron alone (CitationJurgens and McQuade 1992; CitationTramer et al 1998) and in combination with dexamethasone (CitationRoberts and Priestman 1993; CitationKusnierczyk et al 2002).

Gastroenteritis

Gastroenteritis remains a major cause of morbidity and hospitalization in industrialized nations. In the United States, children younger than 5 years have 1 to 2 infections per year, resulting in 1.5 million medical consultations, and 200,000 hospitalizations (CitationPashar et al 1998). Hospitalizations are due to diarrhea and dehydration. Control of vomiting, in order to establish oral rehydration, can be important in counteracting these problems. However, in 1996 the American Academy of Pediatrics reported a consensus opinion that antiemetic medications were not indicated in children with gastroenteritis. They advised caution in prescribing these agents secondary to risk for adverse side-effects (CitationAnonymous 1996).

Randomized, placebo-controlled trials have since demonstrated the efficacy and safety of ondansetron in the treatment of established nausea and vomiting associated with gastroenteritis. CitationReeves et al (2002) studied 107 children 3 months to 22 years of age (mean 5.5 years) and determined a NNT of 5.3 (NA) for cessation of vomiting and 6.25 to prevent hospital admission. In children 6 months to 12 years of age, CitationRamsook et al (2002) demonstrated a NNT of 4.5 (CI 95% 1.2–5.4) for cessation of vomiting and of 8.3 to avoid administration of intravenous fluids. Although oral rehydration therapy remains the primary and essential focus, the Center of Disease Control and the American Academy of Pediatrics now recognize that ondansetron 100–150 µg/kg “can be effective in decreasing vomiting and limiting hospital admission” in gastroenteritis (CitationAnonymous 2004; CitationKing et al 2003).

Other causes of nausea and vomiting

The incidence of opioid induced nausea and vomiting has been reported to range from 20% to 40% depending on medication and patient population (CitationCampora et al 1991; CitationZun et al 2002). High dose ondansetron used in (8–16 mg orally or 1.5 mg/kg intravenously) has shown limited effectiveness in patients receiving neuraxial morphine, a mixture of oral opioid preparations, and morphine patient-controlled analgesia (PCA) with NNT of 3 (CI 95% 2–11), 4.3 (NA), and 3 (CI 95% 2–5), respectively (CitationAlexander et al 1995; CitationSussman et al 1999; CitationTzeng et al 2003). In children, 2–10 years of age, receiving oral transmucosal fentanyl citrate with a PONV of 45%, CitationBinstock and colleagues (2004) were not able to demonstrate a significant antiemetic effect with ondansetron. Similarly, CitationMunro et al (2002) found no response in children, 5–13 years of age, on morphine PCA.

Motion sickness is a common disorder related to confusion between sensory and cognitive functions. Motion sickness affects greater than 50% of children traveling in cars and planes. Symptoms tend to be most severe between 4 and 10 years of age (CitationSetness and Van Beusekom 2004). Although there are no published studies examining the use of ondansetron for this disorder, motion sickness is commonly used as a predictor of PONV and CINV. A meta-analysis performed by CitationFigueredo and Canosa (1999) detected a NNT of 3.4 (CI 95% 2.1–5.4) and 6.4 (NA) for prophylactic ondansetron (4 milligrams, intravenously) to prevent PONV in adult patients with a positive and negative history of motion sickness. This finding suggests a role for ondansetron in preventing and/or reducing the symptoms of motion sickness.

Combination therapy

Contemporary practice guidelines, based on extensive review of randomized control studies, for children at high risk for PONV and CINV recommend ondansetron in conjunction with other antiemetics (CitationCuly et al 2001; CitationDupuis and Nathan 2003; CitationGan et al 2003). Combination therapy is superior to single-drug prophylaxis for PONV and CINV (CitationAlvarez et al 1995; CitationHabib et al 2001). Efficacy can be optimized by taking advantage of the different medications’ mechanisms of action. In a particular, ondansetron in combination with corticosteroids has been shown to be the optimal treatment for PONV associated with tonsillectomies and highly emetogenic chemotherapy agents. Dosing regimes still need to be established but current literature contains the following recommendations for PONV: 150–500 µg (maximum of 10–12 mg) for dexamethasone, 50–75 µg/kg (maximum of 1.25 mg) for droperidol, 500 µg/kg for dimenhydrinate and 70 µg/kg for perphenazine (CitationGan et al 2003). The dose of ondansetron doses (100–150 µg/kg) may be reduced when used in combination with another antiemetic (CitationTramer 2001). Triple combination regiments are recommended for patients at high risk for PONV and CINV. Dosing for antiemetic prophylaxis for CINV include ondansetron 3–5 mg/m2 and dexamethasone 8–16 mg/m2 (Curly et al 2001). Guidelines for prophylactic therapy for children at risk for nausea and vomiting, based on available data from randomized controlled studies and expert consensus, are summarized in .

Table 3 Guidelines for prophylactic therapy for children at risk for nausea and vomiting

Conclusions

Ondansetron has shown good efficacy in the prevention and treatment of nausea and vomiting in young children with exposure to emetogenic agents, which include anesthetic agents, oncologic therapeutics, or viral infections. In children undergoing surgery associated with a high risk of PONV, ondansetron demonstrated superior prophylactic antiemetic efficacy compared with placebo, droperidol, and metoclopramide. It has been demonstrated that ondansetron is relatively free of adverse events. When combined with dexamethasone, ondansetron has been shown to establish almost complete control of emesis. Depending on risk factors for nausea and vomiting, ondansetron, alone or in combination, is the treatment of choice for young children undergoing surgery and chemotherapy.

References

  • AaproM5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatmentOncology2005699710916131816
  • AlexanderRLovellATSeingryDComparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesiaAnaesthesia199550108688546294
  • AlvarezOFreemanABedrosAA double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignanciesJ Pediatr Hematol Oncol199517145507749764
  • AndrewsPLHawthornJThe neurophysiology of vomitingRes Clin Gastroenterol1988214168
  • Anonymous5-HT3 receptor antagonists: a new class of antiemeticsLancet198718548147012885458
  • AnonymousPractice parameter: the management of acute gastroenteritis in young children. American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute GastroenteritisPediatrics199697424358604285
  • AnonymousManaging acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapyPediatrics2004114507
  • AntonarakisESEvansJLHeardGFProphylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence?Pediatr Blood Cancer200443651815390297
  • BinstockWIRubinRBachmanCThe effect of premedication with OTFC, with or without ondansetron, on postoperative agitation, and nausea and vomiting in pediatric ambulatory patientsPaediatr Anaesth2004147596715330959
  • CamporaEMerliniLPaceMThe incidence of narcotic-induced emesisJ Pain Symptom Manage19916428301940487
  • CoatesAAbrahamSKayeSBOn the receiving end: patients’ perception of cancer chemotherapyEur J Cancer Clin Oncol19831920386681766
  • CohenMMCameronCBDuncanPGPediatric anesthesia morbidity and mortality in the perioperative periodAnesth Analg19907016072301747
  • CulyCRBhanaNPloskerGLOndansetron: a review of its use as an antiemetic in childrenPediatric Drugs2001344147911437189
  • DickGSMellerSTPinkertonCRRandomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesisArch Dis Child19957324357492164
  • DominoKBAndersonEAPolissarNLComparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysisAnesth Analg1999881370910357347
  • DupuisLLNathanPCOptions for the prevention and management of acute chemotherapy-induced nausea and vomiting in childrenPediatric Drugs2003559761312956617
  • EberhartLHMorinAMWulfHPatient preferences for immediate postoperative recoveryBr J Anaesth200289760112393775
  • FigueredoECanosaLProphylactic ondansetron for post-operative emesis: meta-analysis of its effectiveness in patients with and without a previous history of motion sicknessEur J Anaesthesiol1999165566410500947
  • FootABMHayesCAudit of guidelines for effective control of chemotherapy and radiotherapy induced emesisArch Dis Child199471475807826125
  • GanTJSelective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?CNS Drugs2005192253815740177
  • GanTJMeyerTApfelCCConsensus guidelines for managing postoperative nausea and vomitingAnesth Analg200397627112818945
  • GoldBSKitzDSLeckyJHUnanticipated admission to the hospital following ambulatory surgeryJAMA19892623008102810644
  • GoodinSCunninghamR5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profileOncologist200274243612401905
  • GreenJAWatkinSWHammondPThe efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomitingCancer Chemother Pharmacol198924137402525078
  • HabibASGanTJCombination therapy for postoperative nausea and vomiting: a more effective prophylaxis?Amb Surg200195971
  • HenziIWalderBTramerMRMetoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studiesBr J Anaesth1999837617110690140
  • HenziIWalderBTramerMRDexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic reviewAnesth Analg2000901869410625002
  • HeskethPJKrisMGGrunbergSMProposal for classifying the acute emetogenicity of cancer chemotherapyJ Clin Oncol19971510398996130
  • HirayamaTIshiiFYagoKEvaluation of the effective drugs for the prevention of nausea and vomiting induced by morphine used for postoperative pain: a quantitative systematic reviewYakugaku Zasshi20011211798511218733
  • HoldsworthMTRaischDWDuncanMHAssessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemiaAnn Pharmacother19952916217711340
  • HoldsworthMTRaischDWFrostJAcute and delayed nausea and emesis control in pediatric oncology patientsCancer20061069314016404740
  • IaconoGMerollaRD’AmicoDGastrointestinal symptoms in infancy: a population-based prospective studyDig Liver Dis200537432815893282
  • JaingT-HTsayP-KHungI-JSingle-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based in pediatric outpatients with acute lymphoblastic leukemiaPediatr Hematol Oncol2004212273515202162
  • JurgensHMcQuadeBOndansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in childrenOncology199249279851387928
  • KhalilSNRothAGCohenITA double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesiaAnesth Analg20051013566116037143
  • KingCKGlassRBreseeJSCenters for disease control and prevention. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapyMMWR Recomm Rep20035211614627948
  • KoseogluVKurekciAESariciUComparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized studyEur J Pediatr1998157806109809818
  • KovacALO’ConnorTAEfficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trialJ Clin Anesth199911453910526822
  • KusnierczykNMSaundersEFDupuisLLOutcomes of antiemetic prophylaxis in children undergoing bone marrow transplantationBone Marrow Transplant2002301192412132051
  • LeeAGinTLauASA comparison of patients’ and health care professionals’ preferences for symptoms during immediate postoperative recovery and the management of postoperative nausea and vomitingAnesth Analg2005100879315616058
  • LeeserJLipHPrevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonistAnesth Analg19917275151827966
  • LermanJSurgical and patient factors involved in postoperative nausea and vomitingBr J Anaesth19926924S321486011
  • LitmanRSWuCLCatanzaroFAOndansetron decreases emesis after tonsillectomy in childrenAnesth Analg199478478818109763
  • MercadanteSSapioMSerrettaROndansetron in nausea and vomiting induced by spinal morphineJ Pain Symptom Manage199816259629803054
  • MunroFJFisherSDicksonUThe addition of antiemetics to the morphine solution in patient controlled analgesia syringes used by children after an appendicectomy does not reduce the incidence of postoperative nausea and vomitingPaediatr Anaesth200212600312358655
  • PandaNBBharadwajNKapoorPPrevention of nausea and vomiting after middle ear surgery: combination of ondansetron and dexamethasone is the right choiceJ Otolaryngol200433889215518095
  • PasharUDHolmanRCBreseeJSEpidemiology of diarrheal disease among children in four West Coast health maintenance organizationsPediatr Infect Dis J199817605119686726
  • ParkerRIPrakashDMahanRARandomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in childrenJ Pediatr Hematol Oncol2001235788111902300
  • PatelRIHannallahRSAnesthetic complications following pediatric ambulatory surgery: a 3-year studyAnesthesiology1988691009123195743
  • PistersKMKrisMGBergerAPortenoyRKWeissmanDETreatment-related nausea and vomitingPrinciples and practice of supportive oncology1998Philadelphia, PALippincott-Raven Publishers
  • PitkanenMTNumminenMKTuominenMKComparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphineEur J Anaesthesiol19971417279088816
  • RamsookCSahagun-CarreonIKozinetzCAA randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritisAnn Emerg Med20023939740311919526
  • ReevesJJShannonMWFleisherGROndansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trialPediatrics200210962
  • RobertsJTPriestmanTJA review of ondansetron in the management of radiotherapy-induced emesisOncology19935017398459988
  • Sanchez-LedesmaMJLopez-OlaondoLPueyoFJA comparison of three antiemetic combinations for the prevention of postoperative nausea and vomitingAnesth Analg2002951590512456422
  • SchnellFMChemotherapy-induced nausea and vomiting: the importance of acute antiemetic controlOncologist200381879812697943
  • SetnessPAVan BeusekomMPatient Notes: motion sicknessPostgrad Med20041166415510594
  • SplinterWRobertsDJProphylaxis for vomiting by children after tonsillectomy: dexamethasone versus perphenazineAnesth Analg19978553479296405
  • StewardDLWelgeJAMyerCMSteroids for improving recovery following tonsillectomy in childrenCochrane Database Syst Rev20031 CD003997
  • StiakakiESavvasSLydakiEOndansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapyPediatr Hematol Oncol199916101810100270
  • SussmanGShurmanJCreedMRIntravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study GroupClin Ther19992112162710463519
  • TramerMRA rational approach to the control of postoperative nausea and vomiting: evidence from systemic reviews. II. Recommendations for prevention and treatment and research agendaActa Anaesthesiol Scand200145141911152027
  • TramerMRReynoldsDJMooreRAEfficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trialsAnesthesiology1997871277899416710
  • TramerMRReynoldsDJStonerNSEfficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic reviewEur J Cancer19983418364410023303
  • TramerMRWalderBEfficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic reviewAnesth Analg19998813546110357345
  • TycVLMulhernRKBierberichAAAnticipatory nausea and vomiting in pediatric cancer patients: an analysis of conditioning and coping variablesJ Dev Behav Pediatr19971827339055147
  • TzengJIChuKSHoSTProphylactic iv ondansetron reduces nausea, vomiting and pruritus following epidural morphine for postoperative pain controlCan J Anaesth2003501023614656780
  • WatchaMFWhitePFPostoperative nausea and vomiting: its etiology, treatment, and preventionAnesthesiology199277162841609990
  • WhiteLAVanaraseMBrockbankKPatient-controlled analgesia and postoperative nausea and vomiting: efficacy of a continuous infusion of ondansetronAnaesth563659
  • WisseloTLStuartCMurisPProviding parents with information before anaesthesia: what do they really want to know?Paediatr Anaesth20041429930715078374
  • ZunLSDowneyLVGossmanWDifferences in narcotic-induced emesis in the EDAm J Emerg Med200220151411992331